CDR Grafted Antibody for Radioimmunotherapy of Lymphoma

This Phase I research will test the hypothesis that an optimum, commercially viable radioimmunotherY-90-radiolabeled cdr-grafted LL2 MAb, targeted against radiosensitive Non-Hodgkin's lymphoma. Y-90because of its desirable radiophysical properties, possible use on an out-patient basis and commercicdr-grafted MAb has been selected in order to minimize human anti-mouse antibody response, which coutreatment. Conjugates will be radiolabeled using a bifunctional chelate based on 2-benzyl-DTPA, sincbe performed in 93- 98 percent incorporation yields within l hour. Y-90-labeled cdr-grafted LL2 willradiolabeled murine LL2 and to the corresponding radioiodinated antibodies for stability; in vitro cinternalization and isotope cellular retention studies, and in vivo in animal tumor xenograft modelsPhase I period, the investigators will have either confirmed the suitability of the Y-90- labeled cdradioimmunotherapy or decided that one of the other agents would be preferred, based on the combinedtumor targeting studies. The final goal is a clinically efficacious, commercially useful, radioimmun